NEW YORK: Potbotics, a data aggregation and technology company focused on the global medical cannabis market, has joined The Blinc Group incubator with the goal of developing adoption and distribution strategies across the US for the first smart dose measuring vaporizer.
A key component of alternative medicine is dosing, and the process can be risky due to the inherent guesswork. Potbotics new approach allows for ultra-precise dosing according to the specific requirements of each individual patient with optimizations for micro-dosing.
Being able to analyze a patient’s use over time will allow the vaporization, whether it’s oil or flower, to be fully customized to their needs. This high quality vaporizing experience enables patients to accurately track how much they inhale in order to deliver consistent and predictable results.
“Blinc Groups market insights, vaporizer know how, and partnerships are a great fit to leverage the disruptive technology Potbotics has been developing for the past three years, ” commented CEO of Potbotics, David Goldstein.
Arnaud Dumas de Rauly, Chief Strategy Officer of The Blinc Group, said “Patients use micro-dosing for a variety of health conditions, that include seizures, autism, and cerebral palsy. Developing a dosaging device is the next big step towards consistency and pinpointing symptoms, we are very proud to be working with Potbotics on this system.”